Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments

Business Wire November 7, 2019

GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting

Business Wire November 6, 2019

GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019

Business Wire October 31, 2019

GlycoMimetics to Present at Two Upcoming Investor Conferences

Business Wire September 5, 2019

GlycoMimetics Reports Top-line Results From Pfizer's Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

Business Wire August 2, 2019

GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

Business Wire August 1, 2019

GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019

Business Wire July 25, 2019

GlycoMimetics to Present at Jefferies 2019 Healthcare Conference

Business Wire May 29, 2019

GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

Business Wire May 6, 2019

GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights

Business Wire May 2, 2019

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

Business Wire April 29, 2019

GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019

Business Wire April 25, 2019

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

Business Wire April 23, 2019

GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359

Business Wire April 22, 2019

GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359

Business Wire April 12, 2019

GlycoMimetics to Present at Upcoming Investor Conferences

Business Wire April 4, 2019

GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019

Business Wire March 7, 2019

GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results

Business Wire March 6, 2019

GlycoMimetics Announces Transition Plan for Board of Directors

Business Wire March 5, 2019

GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019

Business Wire February 27, 2019